Indefinite Delivery Contract SPE2DR25D9761

DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded a single-award Indefinite Delivery Contract (IDC) by the Defense Logistics Agency on November 13, 2025, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The contract, designated SPE2DX, carries a ceiling value of $5.0 million and extends through December 31, 2036, encompassing a 30-month base period with three 30-month option periods. As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group will provide comprehensive pharmaceutical products and medical consumables to support Department of Defense healthcare operations globally, including branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, specialty pharmaceuticals, and medical devices. The contract enables the Defense Logistics Agency to issue firm fixed-price delivery orders for diverse pharmaceutical requirements ranging from routine medications such as antibiotics and antivirals to specialized oncology treatments, immunosuppressants, biologics, emergency medications, and specialty surgical products.

The broader PPV-G GEN V acquisition strategy represents an estimated $30.3 billion procurement initiative designed to establish multiple regional prime vendor contracts supporting Department of Defense medical supply needs across North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet line items. Awards under this solicitation, issued in accordance with NAICS code 424210 and PSC code 6515, were made on a regional basis without set-asides to responsive and responsible offerors based on technical acceptability and lowest overall price considering distribution fees for both brand/generic and specialty pharmaceuticals. DMS Pharmaceutical Group's demonstrated performance on numerous delivery orders issued by the Defense Logistics Agency Medical Supply Chain division between October 2 and October 15, 2025—ranging from under $100 to exceeding $115,000—establishes the company's competitive capability to fulfill the specialized pharmaceutical requirements of military healthcare facilities worldwide under this indefinite delivery contract structure.